|
1
|
Huang Y, Rajappa P, Hu W, Hoffman C, Cisse
B, Kim JH, Gorge E, Yanowitch R, Cope W, Vartanian E, et al: A
proangiogenic signaling axis in myeloid cells promotes malignant
progression of glioma. J Clin Invest. 127:1826–1838. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wick W, Weller M, van den Bent M, Sanson
M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M and
Reifenberger G: MGMT testing-the challenges for biomarker-based
glioma treatment. Nat Rev Neurol. 10:372–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Watkins S and Sontheimer H: Unique biology
of gliomas: Challenges and opportunities. Trends Neurosci.
35:546–556. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang T, Mao Y, Ma W, Mao Q, You Y, Yang
X, Jiang C, Kang C, Li X, Chen L, et al: CGCG clinical practice
guidelines for the management of adult diffuse gliomas. Cancer
Lett. 375:263–273. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Skalsky RL and Cullen BR: Reduced
expression of brain-enriched microRNAs in glioblastomas permits
targeted regulation of a cell death gene. PLoS One. 6:e242482011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ji Y, Vogel RI and Lou E: Temozolomide
treatment of pituitary carcinomas and atypical adenomas: Systematic
review of case reports. Neurooncol Pract. 3:188–195.
2016.PubMed/NCBI
|
|
7
|
Newlands ES, Stevens MF, Wedge SR,
Wheelhouse RT and Brock C: Temozolomide: A review of its discovery,
chemical properties, pre-clinical development and clinical trials.
Cancer Treat Rev. 23:35–61. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chan JA, Stuart K, Earle CC, Clark JW,
Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA,
Zheng H, et al: Prospective study of bevacizumab plus temozolomide
in patients with advanced neuroendocrine tumors. J Clin Oncol.
30:2963–2968. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gilbert MR, Wang M, Aldape KD, Stupp R,
Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT,
et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A
randomized phase III clinical trial. J Clin Oncol. 31:4085–4091.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Khasraw M, Simeonovic M and Grommes C:
Bevacizumab for the treatment of high-grade glioma. Expert Opin
Biol Ther. 12:1101–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen JH, Yu GF, Jin SY, Zhang WH, Lei DX,
Zhou SL and Song XR: Activation of α2 adrenoceptor attenuates
lipopolysaccharide-induced hepatic injury. Int J Clin Exp Pathol.
8:10752–10759. 2015.PubMed/NCBI
|
|
12
|
Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu
L, Deng Y, Lai J, Peng Z, Peng B, et al: Apatinib inhibits VEGF
signaling and promotes apoptosis in intrahepatic
cholangiocarcinoma. Oncotarget. 7:17220–17229. 2016.PubMed/NCBI
|
|
13
|
Kim KL and Suh W: Apatinib, an inhibitor
of vascular endothelial growth factor receptor 2, suppresses
pathologic ocular neovascularization in mice. Invest Ophthalmol Vis
Sci. 58:3592–3599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou N, Liu C, Hou H, Zhang C, Liu D, Wang
G, Liu K, Zhu J, Lv H, Li T and Zhang X: Response to apatinib in
chemotherapy-failed advanced spindle cell breast carcinoma.
Oncotarget. 7:72373–72379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Huang L, Wei Y, Shen S, Shi Q, Bai J, Li
J, Qin S, Yu H and Chen F: Therapeutic effect of apatinib on
overall survival is mediated by prolonged progression-free survival
in advanced gastric cancer patients. Oncotarget. 8:29346–29354.
2017.PubMed/NCBI
|
|
16
|
Allen M, Bjerke M, Edlund H, Nelander S
and Westermark B: Origin of the U87MG glioma cell line: Good news
and bad news. Sci Transl Med. 8:354re3532016. View Article : Google Scholar
|
|
17
|
Nitta Y, Shimizu S, Shishido-Hara Y,
Suzuki K, Shiokawa Y and Nagane M: Nimotuzumab enhances
temozolomide-induced growth suppression of glioma cells expressing
mutant EGFR in vivo. Cancer Med. 5:486–499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dai L, Cui X, Zhang X, Cheng L, Liu Y,
Yang Y, Fan P, Wang Q, Lin Y, Zhang J, et al: SARI inhibits
angiogenesis and tumour growth of human colon cancer through
directly targeting ceruloplasmin. Nat Commun. 7:119962016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dietrich J, Norden AD and Wen PY: Emerging
antiangiogenic treatments for gliomas-efficacy and safety issues.
Curr Opin Neurol. 21:736–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hu X, Zhang J, Xu B, Jiang Z, Ragaz J,
Tong Z, Zhang Q, Wang X, Feng J, Pang D, et al: Multicenter phase
II study of apatinib, a novel VEGFR inhibitor in heavily pretreated
patients with metastatic triple-negative breast cancer. Int J
Cancer. 135:1961–1969. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fontanella C, Ongaro E, Bolzonello S,
Guardascione M, Fasola G and Aprile G: Clinical advances in the
development of novel VEGFR2 inhibitors. Ann Transl Med.
2:1232014.PubMed/NCBI
|
|
22
|
Shankar A, Jain M, Lim MJ, Angara K, Zeng
P, Arbab SA, Iskander A, Ara R, Arbab AS and Achyut BR: Anti-VEGFR2
driven nuclear translocation of VEGFR2 and acquired malignant
hallmarks are mutation dependent in glioblastoma. J Cancer Sci
Ther. 8:172–178. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Alshami J, Guiot MC, Owen S, Kavan P,
Gibson N, Solca F, Cseh A, Reardon DA and Muanza T: Afatinib, an
irreversible ErbB family blocker, with protracted temozolomide in
recurrent glioblastoma: A case report. Oncotarget. 6:34030–34037.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kim SJ, Lee HJ, Kim MS, Choi HJ, He J, Wu
Q, Aldape K, Weinberg JS, Yung WK, Conrad CA, et al: Macitentan, a
dual endothelin receptor antagonist, in combination with
temozolomide leads to glioblastoma regression and long-term
survival in mice. Clin Cancer Res. 21:4630–4641. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Xipell E, Aragón T, Martinez-Velez N, Vera
B, Idoate MA, Martinez-Irujo JJ, Garzón AG, Gonzalez-Huarriz M,
Acanda AM, Jones C, et al: Endoplasmic reticulum stress-inducing
drugs sensitize glioma cells to temozolomide through downregulation
of MGMT, MPG, and Rad51. Neuro Oncol. 18:1109–1119. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Han S, Li Z, Master LM, Master ZW and Wu
A: Exogenous IGFBP-2 promotes proliferation, invasion, and
chemoresistance to temozolomide in glioma cells via the integrin
β1-ERK pathway. Br J Cancer. 111:1400–1409. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Vo VA, Lee JW, Lee HJ, Chun W, Lim SY and
Kim SS: Inhibition of JNK potentiates temozolomide-induced
cytotoxicity in U87MG glioblastoma cells via suppression of Akt
phosphorylation. Anticancer Res. 34:5509–5515. 2014.PubMed/NCBI
|
|
29
|
Wang Z, Sun J, Li X, Yang S, Yue S, Zhang
J, Yang X, Zhu T, Jiang R and Yang W: Downregulation of Src
enhances the cytotoxic effect of temozolomide through AKT in
glioma. Oncol Rep. 29:1395–1398. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu X, Wang L, Chen J, Ling Q, Wang H, Li
S, Li L, Yang S, Xia M and Jing L: Estrogen receptor β agonist
enhances temozolomide sensitivity of glioma cells by inhibiting
PI3K/AKT/mTOR pathway. Mol Med Rep. 11:1516–1522. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zeng H, Yang Z, Xu N, Liu B, Fu Z, Lian C
and Guo H: Connective tissue growth factor promotes temozolomide
resistance in glioblastoma through TGF-β1-dependent activation of
Smad/ERK signaling. Cell Death Dis. 8:e28852017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sato A, Sunayama J, Matsuda K, Seino S,
Suzuki K, Watanabe E, Tachibana K, Tomiyama A, Kayama T and
Kitanaka C: MEK-ERK signaling dictates DNA-repair gene MGMT
expression and temozolomide resistance of stem-like glioblastoma
cells via the MDM2-p53 axis. Stem Cells. 29:1942–1951. 2011.
View Article : Google Scholar : PubMed/NCBI
|
